Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Senzime AB ( (SE:SEZI) ).
Senzime AB has formed a Nomination Committee for its 2026 Annual General Meeting, comprising representatives from major shareholders, including the Crafoord family and Segulah AB. This committee, which represents about 34% of the company’s voting rights, is tasked with preparing proposals for key positions and remuneration ahead of the 2027 AGM, reflecting Senzime’s commitment to structured governance and stakeholder engagement.
The most recent analyst rating on (SE:SEZI) stock is a Hold with a SEK6.00 price target. To see the full list of analyst forecasts on Senzime AB stock, see the SE:SEZI Stock Forecast page.
More about Senzime AB
Senzime is a leading medical device company established in 1999, specializing in precision-based monitoring systems that enhance perioperative patient safety. Their flagship product, the TetraGraph® system, is widely used for accurate neuromuscular transmission monitoring during surgeries. Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market and the US OTCQX Market.
YTD Price Performance: 8.00%
Average Trading Volume: 526,846
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK933.9M
For an in-depth examination of SEZI stock, go to TipRanks’ Overview page.